Earlier this year, Bayer purchased seeds group Monsanto for $63 billion, prompting S&P Global Ratings to cut Bayer’s credit rating. The decision to sell off consumer health brands comes as Bayer looks to lighten its debt load, according to people familiar with the decision cited by Reuters.
Over the last few years, Bayer’s consumer healthcare business has faced falling revenue in the U.S. as consumers switch from buying products at brick-and-mortar drugstores to online retailers. In the first nine months of 2018, Bayer’s consumer health products saw sales decline by 0.4 percent, after seeing declining sales in fiscal year 2017.
In-house specialists are looking to make up for the losses with the possible sale of some of its consumer health assets.
“Bayer is planning to divest consumer health brands in certain countries where it deems its business to be too small to thrive in the long term,” one of the unnamed sources told Reuters.
The drugmaker also is planning to review options for its animal health division to bolster finances.
Read the full report here.
More articles on pharmacy:
5 recent pharma layoffs
Novartis has spent $15B to reinvent itself
AstraZeneca starts search for new CEO under pressure from stakeholders
Becker’s 3rd Annual Fall Chief Pharmacy Officer Summit is the top tier event that the people leading the future of pharmacy convene. This 3-day event is built specifically for Chief Pharmacy Officers and senior pharmacy leaders. The sessions examine the workforce, financial and clinical priorities shaping pharmacy today. Becker’s is where candid discussions flourish and new ideas thrive. Becker's 3rd Annual Fall Chief Pharmacy Officer Summit
